Home
Our Team
News
Menu
Menu
Ottimo Pharma is pioneering first-in-class, uniquely designed and differentiated wide-therapeutic index PD1/VEGFR2 bifunctional medicines to extend the lives of people living with cancer.
Latest News
Ottimo Pharma Raises over $140 Million in Series A Financing
19 December 2024
View all news
Our Team
Contact
info@ottimopharma.com
Scroll to top